TGFB1 and neoplasm: In fact, a 50% reduction of doxorubicin dose was sufficient to produce the same tumor growth inhibition as the full dose when TβRI-KI was added to the treatment suggesting that the combination with TGFβ antagonists may be an effective strategy in reducing doxorubicin dosage and its unwanted side-effects.